Healthcare
In healthcare, a valuation carries both the accounts and a pipeline not yet proven.
In healthcare, a valuation carries both the accounts and a pipeline not yet proven. A single reimbursement decision can reprice a decade of work.
The decision that matters is value today against a future that is real but not yet proved.
Our expertise
The firm has valued healthcare businesses and intellectual property since 2008; its work today applies risk-adjusted income methods, and IFRS/IAS to practices, devices, diagnostics IP and pipeline, including purchase-price allocation and impairment. Every engagement is led by a qualified director and reviewed for independence.
Meet the team behind this work
How we work
We value practices, devices and pipeline IP with risk-adjusted income methods, and test the reimbursement and milestone assumptions that decide value. The client supplies the clinical, regulatory and reimbursement evidence; we set the method and own the review. It fits a funding round, an acquisition, an impairment test or a listing.
View the data
- Scope the asset & purpose
- Choose the method (risk-adjusted income)
- Model reimbursement & milestones
- Independent review
- Report: basis, method, assumptions
What you receive
- A valuation report stating the basis, method and assumptions — what the board, buyer or auditor will test
- Documented reimbursement and milestone assumptions — so the number can be reconstructed
- Enterprise, device and pipeline-IP valuation under IVS 2025 and IFRS/IAS — for funding and reporting
- Purchase-price allocation and impairment support (ASC 805 / IFRS 3; ASC 350 / IAS 36) — for transactions
The reimbursement and milestone assumptions are where value is decided — so we stress-test them first, and say plainly how much of the answer rests on each.
Industry valuation snapshot
Data as of 2026-10-07 · EODHD via apdb data plane · fair-value MCP